ID   KMS-18
AC   CVCL_A637
SY   KMS18
DR   BioSample; SAMN10987762
DR   CCLE; KMS18_HAEMATOPOIETIC_AND_LYMPHOID_TISSUE
DR   Cell_Model_Passport; SIDM01576
DR   CGH-DB; 22-1
DR   CGH-DB; 9134-4
DR   Cosmic; 759902
DR   Cosmic; 2081392
DR   Cosmic; 2081439
DR   Cosmic; 2367277
DR   Cosmic; 2391797
DR   DepMap; ACH-000658
DR   GEO; GSM143334
DR   GEO; GSM290296
DR   GEO; GSM887222
DR   GEO; GSM888296
DR   IARC_TP53; 30102
DR   JCRB; NIHS0483
DR   Wikidata; Q54900170
RX   DOI=10.1002/1438-826X(200005)1:1<48::AID-GNFD48>3.0.CO;2-B;
RX   DOI=10.1016/B978-0-12-221970-2.50457-5;
RX   PubMed=9472091;
RX   PubMed=10936422;
RX   PubMed=11368454;
RX   PubMed=15215163;
RX   PubMed=16956823;
RX   PubMed=17171682;
RX   PubMed=18647998;
RX   PubMed=18700954;
RX   PubMed=19306352;
RX   PubMed=22460905;
RX   PubMed=24504345;
RX   PubMed=30894373;
RX   PubMed=31068700;
CC   Part of: Cancer Cell Line Encyclopedia (CCLE) project.
CC   Characteristics: Produces IgA lambda.
CC   Doubling time: ~72 hours (PubMed=9472091).
CC   Sequence variation: COG1-RNA28S5 (COG1-RN28S1) gene fusion (PubMed=24504345).
CC   Sequence variation: TP53 p.Trp91Ter (c.272G>A) (DepMap).
CC   Omics: Deep exome analysis.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis.
CC   Genome ancestry: African=0%; Native American=0%; East Asian, North=81.47%; East Asian, South=18.53%; South Asian=0%; European, North=0%; European, South=0% (PubMed=30894373).
CC   Discontinued: JCRB; NIHS0483; true.
CC   Derived from sampling site: Peripheral blood.
DI   NCIt; C3242; Plasma cell myeloma
OX   NCBI_TaxID=9606; ! Homo sapiens
SX   Male
AG   60Y
CA   Cancer cell line
DT   Created: 06-06-12; Last updated: 05-07-19; Version: 18
//
RX   DOI=10.1002/1438-826X(200005)1:1<48::AID-GNFD48>3.0.CO;2-B;
RA   Otsuki T., Yamada O., Yata K., Nakazawa N., Taniwaki M., Sakaguchi H.,
RA   Yawata Y., Ueki A.;
RT   "Genetic and biological characterization of human myeloma cell lines:
RT   an overview of the lines established at Kawasaki Medical School.";
RL   Gene Funct. Dis. 1:48-56(2000).
//
RX   DOI=10.1016/B978-0-12-221970-2.50457-5;
RA   Drexler H.G.;
RT   "The leukemia-lymphoma cell line factsbook.";
RL   (In) ISBN 9780122219702; pp.1-733; Academic Press; London (2001).
//
RX   PubMed=9472091; DOI=10.3892/ijo.12.3.545;
RA   Otsuki T., Nakazawa N., Taniwaki M., Yamada O., Sakaguchi H., Wada H.,
RA   Yawata Y., Ueki A.;
RT   "Establishment of a new human myeloma cell line, KMS-18, having
RT   t(4;14)(p16.3;q32.3) derived from a case phenotypically transformed
RT   from Ig A-lambda to BJP-lambda, and associated with hyperammonemia.";
RL   Int. J. Oncol. 12:545-552(1998).
//
RX   PubMed=10936422; DOI=10.1016/S0145-2126(99)00195-2;
RA   Drexler H.G., Matsuo Y.;
RT   "Malignant hematopoietic cell lines: in vitro models for the study of
RT   multiple myeloma and plasma cell leukemia.";
RL   Leuk. Res. 24:681-703(2000).
//
RX   PubMed=11368454; DOI=10.1038/sj.leu.2402097;
RA   Ronchetti D., Bogni S., Finelli P., Lombardi L., Otsuki T.,
RA   Maiolo A.T., Neri A.;
RT   "Characterization of the t(4;14)(p16.3;q32) in the KMS-18 multiple
RT   myeloma cell line.";
RL   Leukemia 15:864-865(2001).
//
RX   PubMed=15215163; DOI=10.1016/S0002-9440(10)63276-2;
RA   Inoue J., Otsuki T., Hirasawa A., Imoto I., Matsuo Y., Shimizu S.,
RA   Taniwaki M., Inazawa J.;
RT   "Overexpression of PDZK1 within the 1q12-q22 amplicon is likely to be
RT   associated with drug-resistance phenotype in multiple myeloma.";
RL   Am. J. Pathol. 165:71-81(2004).
//
RX   PubMed=16956823;
RA   Bataille R., Jego G., Robillard N., Barille-Nion S., Harousseau J.-L.,
RA   Moreau P., Amiot M., Pellat-Deceunynck C.;
RT   "The phenotype of normal, reactive and malignant plasma cells.
RT   Identification of 'many and multiple myelomas' and of new targets for
RT   myeloma therapy.";
RL   Haematologica 91:1234-1240(2006).
//
RX   PubMed=17171682; DOI=10.1002/gcc.20404;
RA   Lombardi L., Poretti G., Mattioli M., Fabris S., Agnelli L.,
RA   Bicciato S., Kwee I., Rinaldi A., Ronchetti D., Verdelli D.,
RA   Lambertenghi-Deliliers G., Bertoni F., Neri A.;
RT   "Molecular characterization of human multiple myeloma cell lines by
RT   integrative genomics: insights into the biology of the disease.";
RL   Genes Chromosomes Cancer 46:226-238(2007).
//
RX   PubMed=18647998; DOI=10.1093/jncimonographs/lgn011;
RA   Dib A., Gabrea A., Glebov O.K., Bergsagel P.L., Kuehl W.M.;
RT   "Characterization of MYC translocations in multiple myeloma cell
RT   lines.";
RL   J. Natl. Cancer Inst. Monogr. 39:25-31(2008).
//
RX   PubMed=18700954; DOI=10.1186/1755-8794-1-37;
RA   Ronchetti D., Lionetti M., Mosca L., Agnelli L., Andronache A.,
RA   Fabris S., Deliliers G.L., Neri A.;
RT   "An integrative genomic approach reveals coordinated expression of
RT   intronic miR-335, miR-342, and miR-561 with deregulated host genes in
RT   multiple myeloma.";
RL   BMC Med. Genomics 1:37-37(2008).
//
RX   PubMed=19306352; DOI=10.1002/gcc.20660;
RA   Lionetti M., Agnelli L., Mosca L., Fabris S., Andronache A.,
RA   Todoerti K., Ronchetti D., Deliliers G.L., Neri A.;
RT   "Integrative high-resolution microarray analysis of human myeloma cell
RT   lines reveals deregulated miRNA expression associated with allelic
RT   imbalances and gene expression profiles.";
RL   Genes Chromosomes Cancer 48:521-531(2009).
//
RX   PubMed=22460905; DOI=10.1038/nature11003;
RA   Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A.,
RA   Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A.,
RA   Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J.,
RA   Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E.,
RA   Raman P., Shipway A., Engels I.H., Cheng J., Yu G.K., Yu J.,
RA   Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C.,
RA   Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C.,
RA   Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N., Mesirov J.P.,
RA   Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L.,
RA   Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M., Golub T.R.,
RA   Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.;
RT   "The Cancer Cell Line Encyclopedia enables predictive modelling of
RT   anticancer drug sensitivity.";
RL   Nature 483:603-607(2012).
//
RX   PubMed=24504345; DOI=10.3892/ijo.2014.2291;
RA   Kobayashi S., Taki T., Nagoshi H., Chinen Y., Yokokawa Y.,
RA   Kanegane H., Matsumoto Y., Kuroda J., Horiike S., Nishida K.,
RA   Taniwaki M.;
RT   "Identification of novel fusion genes with 28S ribosomal DNA in
RT   hematologic malignancies.";
RL   Int. J. Oncol. 44:1193-1198(2014).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z., Monteiro A.N., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=31068700; DOI=10.1038/s41586-019-1186-3;
RA   Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C.,
RA   McDonald E.R. III, Barretina J., Gelfand E.T., Bielski C.M., Li H.,
RA   Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F.,
RA   Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R.,
RA   Lu Y., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C.,
RA   Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A.,
RA   Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D.,
RA   Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L.,
RA   Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A.,
RA   Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D.,
RA   Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M.,
RA   Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R.,
RA   Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A.,
RA   Sellers W.R.;
RT   "Next-generation characterization of the Cancer Cell Line
RT   Encyclopedia.";
RL   Nature 569:503-508(2019).
//